Pharmaceutical

King Charles’ diagnosis raises awareness on prostate co...

UK monarch King Charles was discharged from hospital today following treatment f...

Ascidian launches first-ever clinical study of RNA exon...

An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR st...

STAT+: From a small town in Wales, a scientific sleuth ...

"Wouldn’t you be mad?": What drives Sholto David, the obscure scientist who foun...

STAT+: Merck CEO refused to testify in Senate because h...

Merck's CEO told Sen. Bernie Sanders he wouldn't testify in the Senate because h...

STAT+: Zyn scrutiny from Sen. Chuck Schumer prompts an ...

After Sen. Chuck Schumer raised concerns about Zyn nicotine pouches, conservativ...

Revolutionising healthcare: The role of digital twins

Using digital twins, healthcare professionals can analyse real-time individual h...

CAR-T therapies and cancer risk: No easy answers for th...

CAR-T cell therapies can provide durable cancer remission, however, a recent FDA...

Atossa Therapeutics progresses Phase II preventative br...

Atossa Therapeutics estimates a Q3 Phase II readout for Z-endoxifen, as it plans...

FDA expands approval of Dupixent for eosinophilic esoph...

Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales...

Travere signs $120m licensing deal with Renalys for spa...

Renalys plans to start a registrational trial for sparsentan as a treatment for ...

Drug shortages challenge type 2 diabetes patients in th...

Type-2 diabetes patients continue to be impacted by GLP-1 RA drug shortages in t...

STAT+: Democrats urge government to rein in Medicare Ad...

Sen. Elizabeth Warren wants the government to aggressively change how Medicare A...

STAT+: FTC sues to block a proposed hospital deal in No...

The government sued to block a proposed hospital deal in North Carolina, allegin...

STAT+: Generic group sues Illinois over a price-gouging...

The trade group for generic drug companies in the U.S. filed a lawsuit alleging ...

Merck CEO refused to testify in Senate because he’s not...

Merck's CEO told Sen. Bernie Sanders he wouldn't testify in the Senate because h...

Listen: The plight of the VC, Gilead’s latest setback, ...

This week on "The Readout LOUD": Are venture capitalists OK? Are bolt-ons good f...